Prostate specific membrane antigen (PSMA) regulates angiogenesis independently of VEGF during ocular neovascularization

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Grant, Christina L ^a   Caromile, Leslie A ^a   Durrani, Khayyam ^a   Rahman, M Mamunur ^a   Claffey, Kevin P ^a   Fong, Guo Hua ^a   Shapiro, Linda H ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OXYGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL MOUSE; HYPOXIA; MOUSE; NONHUMAN; NULL ALLELE; OXYGEN INDUCED RETINOPATHY; PHENOTYPE; PROTEIN PROTEIN INTERACTION; RETINA NEOVASCULARIZATION; RETINOPATHY; SIGNAL TRANSDUCTION; WILD TYPE;

ANIMALS; ANOXIA; ANTIGENS, SURFACE; CELL MEMBRANE; GENE EXPRESSION REGULATION; GLUTAMATE CARBOXYPEPTIDASE II; HYDROGEN-ION CONCENTRATION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, BIOLOGICAL; OXYGEN; PEPTIDE HYDROLASES; PERFUSION; PHENOTYPE; RETINA; RETINAL NEOVASCULARIZATION; RETINAL VEIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MUS;

EID: 84864007957     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041285     Document Type: Article

References (52)

1. Nazimul H, Rohit K, Anjli H, (2008) Trend of retinal diseases in developing countries. Expert Review of Ophthalmology 3: 43-50.
2. The Eye Diseases Prevalence Research Group (2004) Causes and Prevalence of Visual Impairment Among Adults in the United States. Arch Ophthalmol 122: 477-485.
3. Ellsbury DL, Ursprung R, (2010) Comprehensive Oxygen Management for the Prevention of Retinopathy of Prematurity: the pediatrix experience. Clin Perinatol 37: 203-215.
4. Jefferies A, (2010) Retinopathy of prematurity: Recommendations for screening. Paediatr Child Health 15: 667-674.
5. Stahl A, Connor KM, Sapieha P, Chen J, Dennison RJ, et al. (2010) The Mouse Retina as an Angiogenesis Model. Investigative Ophthalmology & Visual Science 51: 2813-2826.
6. David E Lederer SWC, Karl G Csaky, (2009) Retina. In: Leonard A. Levin M, PhD, Daniel M Albert, MD, MS, editors. pp. 536-543 editor. Ocular Disease: Mechanisms and Management: Elsevier Ltd.
7. Dhoot DS, Kaiser PK, (2012) Ranibizumab for age-related macular degeneration. Expert Opin Biol Ther 12: 371-381.
8. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, et al. (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364: 1897-1908.
9. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S,et al. Ranibizumab for Diabetic Macular Edema: Results from 2 Phase III Randomized Trials: RISE and RIDE. Ophthalmology.
10. Zachary I, (2005) Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential. Neurosignals 14: 207-221.
11. Arsham Sheybani M, Arghavan Almony, MD, Kevin J. Blinder M, Gaurav K Shah, MD (2010) Anti-VEGF Non-Responders In Neovascular AMD. Review of Ophthamology 17: 52-54.
12. Grossniklaus HE, Kang SJ, Berglin L, (2010) Animal models of choroidal and retinal neovascularization. Prog Retin Eye Res 29: 500-519.
13. Heston WD, (1997) Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase. Urology 49: 104-112.
14. Israeli RS, Powell CT, Fair WR, Heston WD, (1993) Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 53: 227-230.
15. Pinto JT, Suffoletto BP, Berzin TM, Qiao CH, Lin S, et al. (1996) Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 2: 1445-1451.
16. Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH, (1998) Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 83: 2259-2269.
17. Lapidus RG, Tiffany CW, Isaacs JT, Slusher BS, (2000) Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate 45: 350-354.
18. Conway RE, Petrovic N, Li Z, Heston W, Wu D, et al. (2006) Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol 26: 5310-5324.
19. Friedlander M, Theesfeld CL, Sugita M, Fruttiger M, Thomas MA, et al. (1996) Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proceedings of the National Academy of Sciences 93: 9764-9769.
20. Carter RE, Feldman AR, Coyle JT, (1996) Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proceedings of the National Academy of Sciences 93: 749-753.
21. Sahagun G, Moore SA, Fabry Z, Schelper RL, Hart MN, (1989) Purification of murine endothelial cell cultures by flow cytometry using fluorescein-labeled griffonia simplicifolia agglutinin. Am J Pathol 134: 1227-1232.
22. Moeller BJ, Cao Y, Li CY, Dewhirst MW, (2004) Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5: 429-441.
23. Hanahan D, Folkman J, (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364.
24. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, et al. (1999) Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 59: 3192-3198.
25. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, et al. (1997) Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 57: 3629-3634.
26. Grossniklaus HE, Kang SJ, Berglin L, (2010) Animal models of choroidal and retinal neovascularization. Prog Retin Eye Res 29: 500-519.
27. Aguilar E, Dorrell MI, Friedlander D, Jacobson RA, Johnson A, et al. (2008) Chapter 6. Ocular models of angiogenesis. Methods Enzymol 444: 115-158.
28. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, et al. (1994) Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35: 101-111.
29. Chung AS, Ferrara N, (2011) Developmental and Pathological Angiogenesis. Annual Review of Cell and Developmental Biology 27: 563-584.
30. Fuxe J, Tabruyn S, Colton K, Zaid H, Adams A, et al. (2011) Pericyte requirement for anti-leak action of angiopoietin-1 and vascular remodeling in sustained inflammation. Am J Pathol 178: 2897-2909.
31. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, et al. (2001) Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7: 575-583.
32. Duncan GS, Andrew DP, Takimoto H, Kaufman SA, Yoshida H, et al. (1999) Genetic Evidence for Functional Redundancy of Platelet/Endothelial Cell Adhesion Molecule-1 (PECAM-1): CD31-Deficient Mice Reveal PECAM-1-Dependent and PECAM-1-Independent Functions. J Immunol 162: 3022-3030.
33. Marchio S, Lahdenranta J, Schlingemann RO, Valdembri D, Wesseling P, et al. (2004) Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell 5: 151-162.
34. Rangel R, Sun Y, Guzman-Rojas L, Ozawa MG, Sun J, et al. (2007) Impaired angiogenesis in aminopeptidase N-null mice. Proc Natl Acad Sci U S A 104: 4588-4593.
35. Stupack DG, Cheresh DA, (2003) Apoptotic cues from the extracellular matrix: regulators of angiogenesis. Oncogene 22: 9022-9029.
36. Hynes RO, (1999) Cell adhesion: old and new questions. Trends Cell Biol 9: M33-37.
37. Rizzo MT, (2004) Focal adhesion kinase and angiogenesis. Where do we go from here? Cardiovasc Res 64: 377-378.
38. da Silva RG, Tavora B, Robinson SD, Reynolds LE, Szekeres C, et al. (2010) Endothelial α3β1-Integrin Represses Pathological Angiogenesis and Sustains Endothelial-VEGF. The American Journal of Pathology 177: 1534-1548.
39. Kamisasanuki T, Tokushige S, Terasaki H, Khai NC, Wang Y, et al. (2011) Targeting CD9 produces stimulus-independent antiangiogenic effects predominantly in activated endothelial cells during angiogenesis: A novel antiangiogenic therapy. Biochemical and Biophysical Research Communications 413: 128-135.
40. Wilkinson-Berka JL, Jones D, Taylor G, Jaworski K, Kelly DJ, et al. (2006) SB-267268, a Nonpeptidic Antagonist of αvβ3 and αvβ5 Integrins, Reduces Angiogenesis and VEGF Expression in a Mouse Model of Retinopathy of Prematurity. Investigative Ophthalmology & Visual Science 47: 1600-1605.
41. Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD, et al. (2002) Enhanced pathological angiogenesis in mice lacking [beta] 3 integrin or [beta] 3 and [beta] 5 integrins. Nat Med 8: 27-34.
42. Parsons JT, (2003) Focal adhesion kinase: the first ten years. J Cell Sci 116: 1409-1416.
43. Kornberg LJ, Shaw LC, Spoerri PE, Caballero S, Grant MB, (2004) Focal adhesion kinase overexpression induces enhanced pathological retinal angiogenesis. Invest Ophthalmol Vis Sci 45: 4463-4469.
44. Sivakumar B, Harry LE, Paleolog EM, (2004) Modulating angiogenesis: more vs less. JAMA 292: 972-977.
45. Kahook MY, Kimura AE, Wong LJ, Ammar DA, Maycotte MA, et al. (2009) Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surgery Lasers and Imaging 40: 293-295.
46. E. Jason Sabet-Peyman MFMAH, MD; Jennifer E Thorne, MD, PhD; Heather Casparis, MD; Sayjal J Patel, MD; Diana V Do, MD (2009) Progression of Macular Ischemia Following Intravitreal Bevacizumab. Ophthalmic Surgery, Lasers & Imaging 40: 316-318.
47. Rojas C, Frazier ST, Flanary J, Slusher BS, (2002) Kinetics and inhibition of glutamate carboxypeptidase II using a microplate assay. Anal Biochem 310: 50-54.
48. Mesters JR, Barinka C, Li W, Tsukamoto T, Majer P, et al. (2006) Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J 25: 1375-1384.
49. Zhou J, Neale JH, Pomper MG, Kozikowski AP, (2005) NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov 4: 1015-1026.
50. Tsukamoto T, Wozniak KM, Slusher BS, (2007) Progress in the discovery and development of glutamate carboxypeptidase II inhibitors. Drug Discovery Today 12: 767-776.
51. Van Der Post JP, De Visser SJ, De Kam ML, Woelfler M, Hilt DC, et al. (2005) The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693. British Journal of Clinical Pharmacology 60: 128-136.
52. Rojas C, Stathis M, Polydefkis M, Rudek MA, Zhao M, et al. (2011) Glutamate carboxypeptidase activity in human skin biopsies as a pharmacodynamic marker for clinical studies. J Transl Med 9: 27.